trial

Amisulpride in Schizophrenic Acute Phase Patients

NCTId NCT00436371
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 50
Sponsored by Sanofi
Primary completion 2006-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
50
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2005-05
Primary completion
2006-11
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
Amisulpride

Sponsors

SanofiLead Sponsor

Investigators

1
Elaine TangStudy Director

Sites

1 total
Hong Kong, Hong Kong

Facts & assertions

4 sourced
Enrollment
50
Phase
PHASE4
Primary Completion Date
2006-11
Status
COMPLETED
relationships
The graph out of here
drug
Amisulpride
drug
lead_sponsor
Sanofi
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Elaine Tang
person